Ruan Zhang

Ruan Zhang has a wealth of work experience, beginning in 2008 when they served as a Postdoctoral Fellow at the University of Pennsylvania, where they studied the role of PTEN in T cell lymphoma and the role of MyD88 in transplant, as well as using molecular biology and genetic techniques to create CD28-foxed mice. In 2010, they became a Research Fellow at the Beth Israel Deaconess Medical Center. In 2013, they became an Instructor at Massachusetts General Hospital, where they investigated the mechanism of regulatory T cells in regulating B cell activation to prevent autoimmunity and migration of regulatory T cells upon skin inflammation, as well as testing the role of Tregs in MC38 tumor rejection model. In 2016, they became a Staff Scientist at the Dana-Farber Cancer Institute. In 2018, they became a Senior Scientist at FloDesign Sonics. In 2019, they became a Senior Scientist at both TScan Therapeutics and ImmusanT, Inc. In 2020, they became a Director at Cedars-Sinai. Finally, in 2022, they became an Associate Director at hC Bioscience, Inc. and a Principal Scientist at Garuda Therapeutics.

Ruan Zhang obtained a Master's degree in Protein expression and purification from the Shanghai Institute of Biochemistry, Chinese Academy of Science. Ruan then went on to pursue a PhD in Immunology, T cell activation and tolerance induction from the University of Minnesota.